BRISTOL MYERS SQUIBB

Xanomeline and trospium chloride (Cobenfy) showed long-term efficacy and safety in schizophrenia patients, with significant improvements in PANSS scores and tolerability over 52 weeks, making it a promising new treatment option.

Top 20 biopharmaceutical companies saw a 2% market cap increase to $4.3trn in Q3 2024, driven by FDA approvals and strategic alliances, despite some declines.

The 'T-Cell Lymphoma Pipeline Insight Analysis Report' highlights key players like Legend Biotech, Eisai, Takeda, and Rhizen Pharmaceuticals developing treatments such as Lenalidomide, BMS-986369, and Isatuximab SAR650984. Regulatory support, including fast-track designations, drives innovation, aiming for better patient outcomes. The pipeline focuses on immune-modulating drugs, monoclonal antibodies, and targeted therapies, with Phase II trials dominating.

The Clinical Trial Management System Market is projected to grow from USD 1.5 billion in 2022 to USD 4.2 billion by 2031, with a CAGR of 14.6%. Key players include Oracle, IQVIA Inc., and RealTime Software Solutions, LLC. The market focuses on streamlining clinical trial processes, enhancing efficiency, and ensuring compliance.

Redwire Corporation announced the successful return of its third batch of pharmaceutical drug crystals grown in space, including those studied by Eli Lilly using the PIL-BOX platform. These crystals, larger and more ordered than Earth-grown ones, aim to accelerate novel medicine discovery for chronic diseases. Redwire's PIL-BOX system, now with 16 processed units, supports repeatable, scalable crystal manufacturing in space.

The T-Cell Lymphoma Pipeline Insight Analysis Report highlights key players like Legend Biotech, Eisai, Takeda, and Rhizen Pharmaceuticals developing therapies such as Lenalidomide, BMS-986369, and Isatuximab SAR650984. Regulatory support, including fast-track designations, accelerates novel treatment development, aiming to improve patient outcomes in this aggressive cancer.

Beam Therapeutics reports a patient death in BEAM-101 trial for sickle cell disease, unrelated to the therapy. Sana Biotechnology refocuses on autoimmune assets, reducing workforce. Ring Therapeutics expands in Singapore with new deals. Drug regulators criticized for ignoring forced labor in supply chains. OSE Therapeutics' IL-7 therapy shows positive results in ulcerative colitis trial. Japan's PMDA opens second overseas office in Washington.

Evotec SE reports Q3 2024 financial results, highlighting strategic progress despite challenging market conditions. Just - Evotec Biologics shows robust growth, and new partnerships with Pfizer, BMS, and Novo Nordisk are established. The Priority Reset initiative aims for over €40m annualised adjusted EBITDA improvement. A new biologics facility in Toulouse, France, is opened, and full-year 2024 guidance is confirmed.

LaNova Medicines raised $42m in Series C1 funding and outlicensed candidates to AstraZeneca and Turning Point Therapeutics. XellSmart Biomedical secured $28m for stem cell therapies targeting neurodegenerative diseases. BioStar Pharma raised $42m in a Hong Kong IPO for its lead drug Utidelone. Legend Biotech decoupled from GenScript Biotech, citing good corporate governance.